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Renal Transplantation Under FK 506 In African-Americans: 
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J. McCauley, R. Shapiro, H. Woods, V. Scantlebury, W. Irish, J. McMichael, M. Jordan, C. Vivas, 
and T.E. Starzl 
FK 506 is a potent immunosuppressant agent that has demonstrated promising results in liver. heart. and 
kidney transplantation. I African-American patients have. 
in some studies. been found to have lower rena! allograft 
survival rates. Previous experience with cyclosporine 
(CyA) at our center has not suggested that African-Amer-
icans are at a disadvantage after rena! transplantation.2 
Center effect has been invoked by many to explain why 
some centers find differences between racial groups. 3 
Differences in allograft outcome may be related to socio-
economic factors or immunologic differences that might 
leave African-Americans at a disadvantage. Some authors 
have suggested that using more potent immunosuppres-
sant protocols might minimize potential immunologic lim-
itations. Because FK S06 is more potent than CyA, if 
immunologic factors are predominant. allograft survival 
might improve. We reviewed the results of our early 
experiences with FK S06 to characterize the outcomes of 
African-American rena! transplant patients and compared 
these results to CyA-treated patients. 
PATIENTS AND METHODS 
From October 1987 until October 1992 9S7 patients received renal 
transplants at the University of Pittsburgh. During this period 131 
African-American patients were transplanted; 48 with FK 506 + 
prednisone. 13 with CyA + prednisone. 54 with CyA triple 
therapy. and 16 with FK S06-based triple therapy. The frequency 
of immunosuppression protocols was simiJarly distributed for 
white pauents. The immunosuppression protocols and results of 
previous tnals have been published elsewhere.·" The FK 506 
doses used in these protocols are now believed to be excessive 
and led to nephrotoxicity and other side elfccts that have been 
minimized by lowering doses.6 Dilferenc:e between mean values 
was evaluated using Student's t test or anal.ysis of variance when 
appropriate. Cox regression modeling was used to evaluate the 
contribution of multiple facton on allograft survival. 
RESULTS 
Allograft survival was similar for FK 506 and CyA-treated 
African-American patients (Fig I). There was no differ-
ence in waiting time. recent or highest panel reactive body 
(PRA). number of previous transplants. age or sex be-
tween these groups. There was likewise no difference in 
allograii survival when African-American patients were 
compared to whites. In this analysis aU white patients and 
all African-American patients were pooled into their re-
spective groups. There was also no significant difference in 
patient survival between races or between treatment pro-
tocols when all patients were pooled. In both analyses 
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fig 1. Allograft survival in African-American patients by immuno-
suppression protocol. 
there was no difference in age, sex, waiting time. highest or 
PRA prior to transplantation (recent PRA), or allograft 
number. 
Cox regression modeling was used to determine the 
variables that predicted allograft survival. The following 
variables were considered: age, sex. race. native kidney 
diagnosis. highest PRA. recent PRA. cadaveric vs living 
related. allograft number, and immunosuppression proto-
col. The only variable that improved the model. of those 
listed. was recent PRA. Importantly, race was not a 
significant factor in predicting aUograft survival. 
DISCUSSION 
Race has been implicated as a major predictor of aUograft 
survival in renal transplantation. Studies conducted during 
the last decade have not universally found this to be true. 
The concept of center elIect has grown from this variabil-
ity. Center elIect does not. however. explain the reasons 
for these differences. Most investigators have found socio-
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economic factors to be important and may predominate. 
Immunologic factors have also been implicated. Some 
investigators have suggested that enhanced immunosup-
pression may be required in African-Americans given the 
genetic differences between these recipients and their 
white donors. FK S06, a more potent immunosuppressant. 
would seem to be an ideal choice if the latter hypodlesis 
were true. We have found. however. no difference in 
allograft survival between FK S06-treated patients and 
their Cy A counterparts. Likewise, there was no difference 
in allograft survival between African-Americans and 
whites in this study. These data suggest that. at least in this 
center. any differences in immunologic or socioeconomic 
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factors were not sufficient to reduce the long-term out-
come of renal transplantation in African-Americans. 
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